Category: pharmacological
Aliases: Leqvio
GalNAc-conjugated small interfering RNA. GalNAc moiety targets asialoglycoprotein receptor on hepatocytes → selective hepatic uptake. siRNA silences PCSK9 mRNA → preserves hepatic LDLR → 50% LDL reduction. Twice-yearly dosing — extraordinary convenience vs mAb PCSK9 inhibitors (every 2–4 weeks).
SC: 9h